Core Viewpoint - A class action lawsuit has been filed against Marex Group plc, alleging that the company concealed losses and inflated profits through deceptive financial practices during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague on behalf of investors who purchased Marex shares from May 16, 2024, to August 5, 2025 [1][2]. - Investors have until December 8, 2025, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations and Impact - NINGI Research published a report on August 5, 2025, claiming that Marex used off-balance-sheet entities and fictitious intercompany transactions to hide losses and inflate profits [3]. - Following the report, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31, resulting in significant investor losses [3].

Core Viewpoint - WPP plc is facing a class action lawsuit due to allegations of providing misleading statements about its media arm's performance, leading to a significant drop in stock price after a disappointing trading update [1][2]. Summary by Sections Allegations - The complaint claims that WPP's management made overly positive statements while concealing adverse facts about the company's ability to handle macroeconomic challenges and competition, resulting in a loss of market share [1]. - On July 9, 2025, WPP reported a deterioration in performance for Q2 2025, attributing this to macroeconomic uncertainty and weaker new business, compounded by distractions from ongoing restructuring efforts [1]. Stock Performance - Following the trading update on July 9, 2025, WPP's stock price plummeted from $35.82 per share to $29.34 per share, marking an approximate decline of 18.1% in just one day [1]. Class Action Details - Shareholders who purchased WPP shares during the class period from February 27, 2025, to July 8, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff applications set for December 8, 2025 [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) for allegedly issuing false and misleading statements regarding its drug candidate SLK during the class period from March 10, 2024, to September 29, 2025 [1]. Summary by Sections Allegations - The complaint alleges that the defendants failed to disclose that SLK and BIMZELX share the same molecular targets, specifically the inflammatory cytokines IL-17A and IL-17F [1]. - It is claimed that SLK's unique Nanobody structure would not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [1]. - The assertion is made that SLK's supposed increased tissue penetration would not lead to improved clinical efficacy [1]. - Based on these points, the defendants are said to lack a reasonable basis for their positive statements regarding SLK's superiority to monoclonal antibodies [1]. Class Action Details - Shareholders who purchased shares of MLTX during the specified class period are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [1]. - The deadline for shareholders to register for the class action is December 15, 2025 [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and engage in good corporate citizenship [3].

Core Insights - Tronox Holdings plc (NYSE: TROX) is facing a class action lawsuit due to allegations of providing misleading statements about its financial health and sales forecasts, particularly regarding its TiO2 and zircon products [2][4] - The company reported a significant decline in TiO2 sales for Q2 2025, attributing this to a weaker coatings season and increased competition, leading to a downward revision of its 2025 financial outlook and a 60% reduction in dividends [2][3] - Following the announcement of poor financial results, Tronox's stock price plummeted approximately 38% from $5.14 to $3.19 per share in just one day [2] Company Overview - Tronox's class period for the lawsuit is defined as February 12, 2025, to July 30, 2025, during which shareholders are encouraged to register for potential recovery [3] - The Gross Law Firm is representing the shareholders, emphasizing its commitment to protecting investors from deceitful practices and ensuring corporate accountability [4] Next Steps for Shareholders - Shareholders who purchased shares during the specified class period must register by November 3, 2025, to be considered for lead plaintiff status, with no cost or obligation to participate [3]

Accessibility StatementSkip Navigation PHILADELPHIA, Oct. 27, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Accessibility StatementSkip Navigation SAN DIEGO, Oct. 27, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Peters v. MoonLake Immunotherapeutics, No. 25-cv-08612, and pending in the Southern District of New York – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake as well as certain of MoonLake's top executives with violations of the Securities Exchange Act of 1934. http ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws, particularly concerning misleading statements about its product SLK compared to BIMZELX [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against MoonLake [4]. - Investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, are encouraged to contact the firm to discuss their legal rights [1][9]. - The complaint alleges that MoonLake and its executives made false statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [6]. Group 2: Stock Performance and Market Reaction - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [7]. - The results indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, leading to significant investor losses [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational footprint [5].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Clinical Data and Claims - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab compared to competitors [4]. - The company asserted that the Nanobody structure of SLK provided beneficial differences over traditional monoclonal antibody treatments [4]. Allegations and Discrepancies - The lawsuit alleges that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75, nearly 90%, from $61.99 to $6.24 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that defendants made false or misleading statements regarding the efficacy of their product compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and providing unrealistic financial guidance for 2025, leading to significant investor losses when the truth was revealed [3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague on behalf of investors who acquired LifeMD shares between May 7, 2025, and August 5, 2025 [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representatives [2]. - The complaint alleges that LifeMD did not disclose rising customer acquisition costs associated with its RexMD platform and its promotion of obesity medications like Wegovy and Zepbound [3]. Group 2: Company Background - LifeMD, headquartered in New York, provides virtual medical services and prescription delivery [2]. - The firm has been accused of making materially false and misleading statements throughout the class period, lacking a reasonable basis for its claims [3].